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Abstract 
A 63-year-old female presented with abnormal lung shadows but had, apart from this, 
few symptoms. Computed tomography (CT) revealed multiple nodules and blockage of 
the pulmonary artery. She was immediately diagnosed with pulmonary artery sarcoma 
based on a careful differential diagnosis and underwent surgery. Her tumor was 
pathologically diagnosed as leiomyosarcoma (i.e. intimal sarcoma). Pulmonary artery 
sarcoma can be easily confounded with thromboembolism in a clinical setting and some 
cases are diagnosed post mortem only. In our case, clinical prediction scores (Wells score, 
Geneva score, and revised Geneva score) for the pulmonary embolism showed low 
probability. Moreover, chest CT showed uncommon findings for pulmonary 
thromboembolism, as the nodules were too big for thrombi. Because surgical resection 
can provide the only hope of long-term survival in cases of pulmonary artery sarcoma, 
clinicians should consider this possibility in the differential diagnosis of pulmonary 
embolism. Clinical prediction scores and CT findings might help to reach the correct 
diagnosis of pulmonary artery sarcoma. Case Rep Oncol 2011;4:287–298 
DOI: 10.1159/000328994 
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Introduction 
Primary pulmonary artery sarcomas are very rare and aggressive neoplasms. 
Morphologically, there are at least ten reported subtypes of pulmonary artery sarcoma: 
undifferentiated sarcoma, leiomyosarcoma, rhabdomyosarcoma, fibrosarcoma, 
myxosarcoma, malignant mesenchymoma, chondrosarcoma, angiosarcoma, 
osteosarcoma, and malignant fibrous histiocytoma [1, 2]. The tumors appear to arise from 
multipotential mesenchymal cells of the bulbus cordis [2, 3]. There is evidence that the 
intima of the small arteries contain primitive mesenchymal cells with potential for 
multidirectional differentiation [4]. 
Leiomyosarcoma is a malignant tumor composed of smooth-muscle cells. The most 
common locations of soft tissue leiomyosarcoma are the retroperitoneal and the pelvic 
region. Another distinctive subgroup consists of leiomyosarcomas that arise in large 
blood vessels, most commonly the inferior vena cava and the large veins of the lower 
extremities. Arterial origin has been observed, but is rare; sarcomas of the pulmonary 
artery and other large arteries have distinct features and are better classified as intimal 
sarcomas [5, 6]. 
Primary pulmonary artery sarcoma is easily confounded with pulmonary 
thromboembolism in a clinical setting. Many patients initially receive anticoagulant 
therapy but fail to respond, and many are diagnosed post mortem only. We report a case 
of pulmonary intimal sarcoma that could be promptly diagnosed by careful consideration 
of the differential diagnosis. 
Case Report 
A 63-year-old female was admitted to our hospital after abnormal lung shadows were discovered 
during a routine annual medical checkup. Two months before her admission, she had experienced 1 
episode of slight chest tightness. She was a housewife who had never smoked. Thirteen years previously, 
she had been diagnosed with rheumatoid arthritis and had been taking prednisolone (1 mg) and 
salicylazosulfapyridine for 10 years and methotrexate for 4 years. Her vital signs on admission were a 
temperature of 36.7°C, a blood pressure of 127/90 mm Hg, a pulse of 84 beats per minute, and an 
oxygen saturation measured by pulse oximeter (SpO2) of 94.3%. On physical examination she presented 
with ulnar drift deformities in fingers of both hands. Her lungs were clear on auscultation and her 
cardiac sound was a regular rhythm without heart murmur. Laboratory findings indicated slight 
inflammation, with a white blood cell count of 9,300 per microliter and C-reactive protein of 2.3 mg/dl 
(table 1). The results of arterial blood gas were as follows: pH, 7.429; partial pressure for oxygen (PaO2), 
69.3 mm Hg; partial pressure for carbon dioxide (PaCO2), 38.4 mm Hg; bicarbonate content (HCO3
–), 
25.0 mEq/l. Tumor markers inluding carcinoembryonic antigen (CEA), cytokeratin fragment 19 
(CYFRA), pro-gastrin releasing peptide (ProGRP), sialyl Lewis X-i antigen (SLX), squamous cell 
carcinoma antigen (SCC), and neuron-specific γ-enolase (NSE), were within normal limits. 
Electrocardiography revealed a right atrial enlargement. Chest radiography showed a mass in the left 
upper lung field (fig. 1a) and reduced blood vessel distribution in the left lower lung field. Computed 
tomography (CT) scanning of the chest revealed multiple nodules in the left lung (fig. 1b, c) and low-
density lesions occupying the pulmonary artery (fig. 1d). In magnetic resonance imaging (MRI), mass 
lesions with a low-density appearance in T1-weighted images and high-density appearance in T2-
weighted images were spread across the pulmonary arteries in the left upper lobe (fig. 2a, b). Lung 
perfusion scintigraphy revealed perfusion defect in the left whole lung and focal perfusion defect in the 
right lung (fig. 2c). F-18-2-fluoro-2-deoxyglucose positron emission tomography (FDG-PET) showed 
multiple mass lesions in the lung fields and mediastinum (fig. 2d, e). The maximal standard uptake 
value (SUVmax) was 2.6. Transthoracic echocardiography revealed pulmonary hypertension (the 
predicted right ventricular systolic pressure was 49 mm Hg) with pulmonary artery dilation, moderate 
pulmonic valve regurgitation, moderate tricuspid valve regurgitation, mild mitral valve regurgitation, Case Rep Oncol 2011;4:287–298 
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May 27, 2011 
© 2011 S. Karger AG, Basel
ISSN 1662–6575 
www.karger.com/cro   
 
 
 
289
dilation of the left atrium, right atrium and right ventricle, and concentric left ventricular hypertrophy 
(fig. 2f). In flexible bronchoscopy, the trachea and left main bronchus were slightly pressed rightward. 
The mucosa in the upper division of the left upper lobe was irregular, suggesting tumor invasion. The 
pulmonary trunk was difficult to detect by endobronchial ultrasonography (EBUS), but the EBUS 
examination clearly showed a tumorous mass within the left pulmonary artery. A high risk of 
complications prevented us from biopsying the mass intravascularly. 
We decided to intervene surgically, as the findings suggested a diagnosis of primary pulmonary 
artery sarcoma rather than a pulmonary embolism. Exploration of the pulmonary artery under cardio-
pulmonary bypass revealed a tumor in the left pulmonary artery with a thickened arterial wall invaded 
by the tumor. The anterior walls of both the main and right pulmonary arteries were resected as much 
as possible and reconstructed with an autologous pericardial patch with a 5-0 monofilament continuous 
suture. The tumor had infiltrated the right distal pulmonary artery, which prevented any attempt of 
complete tumor resection under the guidance of intraoperative pathological diagnosis. A left lobectomy 
was performed thereafter. 
The gross section (fig. 3a) of the tumor was clear ivory-white with necrosis and hemorrhage. The left 
pulmonary artery was dilated to 2.5 cm in width by an intraluminal tumor (6.5 × 2.5 × 2.5 cm) that 
extended through the pulmonary arteries into the distal lung parenchyma. There was a contiguous well-
defined 3.5 cm mass consisting of several nodules in the lung. Several nodules in the left upper lobe 
remained within the pulmonary arteries, but most of the tumors extended into the lung parenchyma, 
forming an ill-defined mass. The tumor in the lower lobe extended mainly through the pulmonary 
artery and formed an ill-defined 2.5 cm mass at the superior segment in the lower lobe. Patchy 
pulmonary infarction lesions spread across both the upper and lower lobes. 
Microscopically, the tumor was composed of spindle- or circular-shaped cells with cigar-shaped 
nuclei and elongated cytoplasm (fig. 3b). Two patterns of tumor growth were observed in the lung 
parenchyma: some tumors extended into the alveolar septum and interalveolar septum, forming a 
reticular pattern, while others grew solidly within the alveolar space. Tumor embolisms with cavities 
and necrosis surrounded by viable tumor cells were observed in both the upper and lower lobes. A 
fungal abscess of 15 × 5 mm in size, possibly aspergillus, was connected to the bronchioles in the left 
superior lobe anterior segment. No pathological lesions suggestive of pulmonary thromboembolism 
were evident. Immunohistochemical staining for alpha smooth muscle actin (α-SMA) and desmin, two 
markers for mesenchymal neoplasms, were focally positive in the pleomorphic cancer cells (fig. 3c, d). 
Immunohistochemical staining for CD99 was partially positive in the spindle cancer cells. 
Immunohistochemical staining for CD31 PECAM-1, CD34 (endothelial cell marker), myosin, CD57, S-
100, and epithelial markers (including cytokeratins; CAM5.2, AE1/AE3, CK7, CK19) and EMA 
(epithelial membrane antigen) were negative. Immunohistochemical staining for BCL-2 was positive 
and the Ki-67 labeling index (the percentage of positive cells stained with proliferation marker Ki-67 
antibody) was 40% (fig. 3e), suggesting that the tumor had aggressive characteristics. The patient was 
diagnosed with primary pulmonary artery sarcoma with smooth muscle differentiation compatible with 
leiomyosarcoma (i.e. intimal sarcoma). Complete tumor resection was impossible, and the patient had 
developed an aplastic anemia that prevented us from administering other therapies. The tumor in the 
right pulmonary artery gradually grew and metastasized to the liver. The patient died 14 months after 
the operation. 
Discussion 
Primary pulmonary artery sarcomas are very rare tumors: no more than about 150 
cases have been reported in English-language literature [1–3, 7, 8]. The differential 
diagnoses include pulmonary artery sarcoma, thromboembolism, and lung cancer. The 
symptoms of the pulmonary embolism are nonspecific. Laboratory findings have a low 
diagnostic specificity and chest radiograph is generally nondiagnostic. Scores derived 
from explicit prediction rules that combine clinical findings at presentation with 
predisposing factors (table 2) have proved useful in determining the clinical or pretest 
probability of pulmonary embolism. The Wells score [9], Geneva score [10], and revised 
Geneva score [11] have been recommended as diagnostic criteria [12]. Our patient Case Rep Oncol 2011;4:287–298 
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experienced only a slight tightness of the chest before admission, and her physical 
examination on admission produced no findings suggestive of pulmonary embolism. 
Laboratory findings revealed slight leukocytosis, elevated levels of lactate dehydrogenase, 
and slight hypoxemia without hypocapnia. The clinical prediction scores for acute 
pulmonary embolism (table 2) indicated a low probability: the Wells score was 0, the 
Geneva score 4, and the revised Geneva score 3. Only one of three separate measurements 
of D-dimer levels by quantitative latex agglutination, a moderately sensitive D-dimer 
assay, revealed an elevation, and the elevation was slight: 1.23, 0.99, and 0.77 μg/ml, 
respectively (reference range from 0 to 1 μg/ml). We propose that pulmonary artery 
sarcomas should be strongly suspected in cases who present with mass lesions in the 
pulmonary arteries but score low on the clinical prediction indexes and have low D-dimer 
levels. 
We believe that the left pulmonary artery had become occluded gradually over time in 
this case. Had the occlusion been sudden, the patient would have suffered severe and 
possibly fatal distress. As it turned out, she complained of few symptoms and manifested 
no signs of occlusion such as tachypnea, wheezing, or tachycardia. Her 
electrocardiographic abnormalities, meanwhile, were very trivial. We can presume, 
therefore, that she adapted to the gentle and quiet progression of the left pulmonary 
artery occlusion. Pulmonary embolisms usually arise from venous thrombosis, but our 
patient had no history of thromboembolism, nor signs or symptoms of deep venous 
thrombosis such as leg pain, warmth, or swelling. She was also free from any risk factors 
for thromboembolism. 
Several indicators on CT and MRI favor the diagnosis of pulmonary artery sarcoma 
over chronic thromboembolic disease [13]. In contrast to the abrupt vascular narrowing 
and cutoff in embolic disease, sarcomas form a contiguously soft tissue-filled pulmonary 
artery, sometimes with vascular distension and extravascular spread. Unilateral central 
pulmonary embolus is uncommon. Pulmonary artery sarcomas are more likely to have a 
heterogeneous appearance from areas of necrosis, hemorrhage, and ossification 
(especially osteosarcoma/chondrosarcoma). Enhancement after gadopentetate 
dimeglumine in the MRI examination is suggestive of sarcoma instead of 
thromboembolic disease, which does not enhance. 
Most of the nodular shadows in our patient were located proximal to the left lungs on 
the chest CT. This suggested that the tumor emboli had had a certain amount of volume, 
had been trapped in the relatively large pulmonary arteries and had invaded the 
surrounding lung tissues. This was an uncommon chest CT finding for pulmonary 
thromboembolism, as the nodules were too big for thrombi (thrombi are normally about 
the same size as the pulmonary arteries). Ito et al. [14] reported that FDG-PET could 
discriminate pulmonary artery sarcoma from pulmonary embolism based on SUVmax: 
SUVmax of the pulmonary artery sarcomas was 7.63 ± 2.21, whereas the SUVmax of the 
pulmonary embolisms was 2.31 ± 0.41. However, the SUVmax of the tumor in our case 
was 2.6. 
Differential diagnosis also included primary and metastatic lung cancer. Our patient 
never smoked and her serum tumor markers (CEA, CYFRA, SLX, SCC, NSE, and 
ProGRP) were all within normal ranges. If the multiple nodules in the left lung were 
metastases, they probably originated from the left main pulmonary artery. If they had 
come directly from the general circulation, they would have metastasized to both lungs Case Rep Oncol 2011;4:287–298 
DOI: 10.1159/000328994 
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diffusely. It would be unlikely for a cancer of this type to first metastasize to the left main 
pulmonary artery, grow there, and then metastasize again to the left lung. Moreover, our 
FDG-PET and other examinations failed to detect any primary cancers capable of 
developing blood-borne metastasis to the left main pulmonary artery. 
We postulate that the actual prevalence of pulmonary artery sarcoma is much higher 
than the estimated prevalence, as pulmonary artery sarcoma is difficult to diagnose and 
often goes unidentified without autopsy. The prognosis for patients with pulmonary 
artery sarcoma is poor. In most series, the mean survival time is less than 2 years. 
Whether treatments with chemotherapy or radiation therapy affect prognosis is unclear, 
as randomized trials of these tumors are not available to guide therapy. Radical surgical 
resection seems to provide the only hope of long-term survival [15]. 
Conclusion 
Clinicians must be mindful of pulmonary artery sarcoma when making the differential 
diagnosis for patients with mass lesions in the pulmonary arteries. The clinical prediction 
scores (Wells score, Geneva score, and revised Geneva score) and the CT findings can 
help to identify the patients with pulmonary artery sarcoma. 
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Table 1. Laboratory tests on admission 
 Value    Reference
a 
Hematologic examination    
White blood cells, /mm
3  <9,300 (3,600–9,300) 
Differential count, %     
Neutrophils  <75.7 (41.7–74.1) 
Lymphocytes  <16 (18.9–47.7) 
Monocytes  <7.2 (3.6–8.5) 
Eosinophils  <0.8 (0.6–8.5) 
Basophils  <0.3 (0.0–1.5) 
Atypical lymphocytes  <0 (0) 
Hemoglobin, g/dl  <12.9 (12–15) 
Hematocrit, %  <38.3 (34–45.3) 
Platelet count, ×10
4/mm
3  <18.1 (12–41) 
Chemical constituents of blood    
Total protein, g/dl  <6.5 (6.6–8.1) 
Albumin, g/dl  <3.7 (4.1–4.9) 
Urea nitrogen, mg/dl  <14 (7–19) 
Creatinine, mg/dl  <0.45 (0.7–1.1) 
Sodium, mmol/l  <139 (138–146) 
Potassium, mmol/l  <4.3 (3.7–5.0) 
Chloride, mmol/l  <99 (99–107) 
Calcium, mg/dl  <9.3 (9.2–10.7) 
Lactate dehydrogenase, U/l  <249 (109–210) 
Alanine aminotransferase, U/l  <28 (13–35) 
Aspartate aminotransferase, U/l  <19 (8–48) 
Alkaline phosphatase, U/l  <335 (104–338) 
Bilirubin total, mg/dl  <0.7 (0.3–1.2) 
Glucose, mg/dl  <72 (75–107) 
Creatine kinase, U/l  <67 (35–175) 
Glycosylated hemoglobin A1c, %  <4.4 (4.3–5.8) 
Soluble IL-2 receptor  <836 (220–530) 
Angiotensin-converting enzyme  <10.8 (8.3–21.4) 
KL-6, U/l  <162 (0–500) 
SP-D, ng/ml  <17.2 (0–110) 
(1→3)-β-D-glucan, pg/ml  <6.0  (0–20) 
Cryptococcus antigen  <negative (negative) 
Candida antigen  <negative (negative) 
Aspergillus antigen  <0.3 (0–1.0) 
Serology    
C-reactive protein, mg/dl  <2.3 (≤0.3) 
IgG, mg/dl  <975 (868–1,780) 
IgM, mg/dl  <50 (57–310) 
IgA, mg/dl  <250 (122–412) 
Rheumatoid factor, IU/ml  <52 (0–20) 
Rheumatoid arthritis particle agglutination, dilution factor  <160 (0–40) 
Tumor markers    
Carcinoembolinic antigen, ng/ml  <0.5 (0–5) 
Cytokeratin fragment 19, ng/ml  <1.0  (0–3.5) 
Sialyl Lewis X-i antigen, U/ml  <21 (0–38) 
Squamous cell carcinoma antigen, ng/ml  <0.5  (0–1.5) 
Neuron-specific γ-enolase, ng/ml  <5.4 (0–10) 
Pro-gastrin releasing peptide, ng/ml  <14.4 (0–46) 
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Table 1 (continued) 
 Value    Reference
a 
Coagulation    
Protein C, %   <100 (62–131) 
Protein S, %   <72 (60–127) 
Anti-cardiolipin-β2-glycoprotein I complex  ≤1.2  (0–3.5) 
Brain natriuretic peptide, pg/ml  <45.6 (0–18.4) 
Prothrombine time, s  <10.9 (9–11) 
International normalized ratio  <1.17 (0.9–1.1) 
Activated partial-thromboplastin time, s  <32.5 (24.5–39.7) 
D-Dimer, μg/ml  <1.23 (0–1) 
Antithrombin III, %  <91.5 (80–125) 
Arterial blood gas analysis (room air)    
pH  <7.429 (7.35–7.45) 
Partial pressure of oxygen, Torr  <69.3 (80–100) 
Partial pressure of carbon dioxide, Torr  <38.4 (35–42) 
Base excess, mmol/l  <1.2  (–2.0 to 2.0) 
a Range, number, or negative/positive. 
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Table 2. Clinical prediction scores for pulmonary embolism 
Canadian (Wells) prediction score   
Variable and score   
3.0  Symptoms and signs of deep vein thrombosis 
3.0  Pulmonary embolism more likely than alternative diagnosis 
1.5  Heart rate >100 beats/min 
1.5  Previous deep vein thrombosis or pulmonary embolism 
1.5  Recent immobilization or surgery (≤4 weeks) 
1.0 Hemoptysis 
1.0 Cancer 
Total score   
<2.0 Low  probability  (1.3%) 
<2.0–6.0 Moderate  probability  (16.2%) 
>6.0  High pretest probability (37.5%) 
Original Geneva (Wicki) score   
Variable and score   
1  Age 60–79 years 
2 Age  ≥80  years 
2  Previous deep vein thrombosis or pulmonary embolism 
3 Recent  surgery 
1  Heart rate >100 beats/min 
2 PaCO2 <36.2 mm Hg (<4.8 kPa) 
1 PaCO2 36.2–38.9 mm Hg (4.8–5.19 kPa) 
4 PaO2 <48.8 mm Hg (<6.5 kPa) 
3 PaO2 48.8–59.9 mm Hg (6.5–7.99 kPa) 
2 PaO2 60–71.2 mm Hg (8.0–9.49 kPa) 
1 PaO2 71.3–82.4 mm Hg (9.5–10.99) 
1  Platelike atelectasis in chest radiograph 
1  Elevation of hemidiaphragm in chest radiograph 
Total score   
<5 Low  probability  (10%) 
<5–8 Moderate  probability  (38%) 
>8 High  probability  (81%) 
Revised Geneva score   
Variable and score   
1  Age >65 years 
3  Previous deep vein thrombosis or pulmonary embolism 
2  Surgery or lower limb fracture in previous weeks 
2 Active  cancer 
3  Unilateral lower limb pain 
2 Hemoptysis 
Total score   
<4 Low  probability  (8%) 
<4–10 Moderate  probability  (28%) 
>10 High  probability  (74%) 
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Fig. 1. Chest radiography shows a mass in the left upper lung field (a). CT scans of the chest reveal 
multiple nodules in left lung (b, c) and low-density lesions occupying the pulmonary artery (d). 
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Fig. 2. MRI reveals mass lesions spreading across the pulmonary arteries in the left upper lobe. The 
lesions have a low-density appearance in the T1-weighted image (a) and a high-density appearance in 
the T2-weighted image (b). Lung perfusion scintigraphy reveals a perfusion defect in the left whole lung 
and a focal perfusion defect in the right lung (c). FDG-PET shows multiple mass lesions in the lung 
fields and mediastinum (d, e) with a SUVmax of 2.6. Transthoracic echocardiography shows 
pulmonary hypertension with dilation of the left atrium, right atrium, and right ventricle, and 
concentric left ventricular hypertrophy (f). 
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Fig. 3. Gross section shows a clear, ivory-white tumor with necrosis and hemorrhage (a). The left 
pulmonary artery is dilated to a width of 2.5 cm by an intraluminal tumor (6.5 × 2.5 × 2.5 cm) extending 
through the pulmonary arteries into the distal lung parenchyma. The tumor is composed of spindle- or 
circular-shaped cells with cigar-shaped nuclei and elongated cytoplasm (b). Immunohistochemical 
stainings for α-SMA (c) and desmin (d) are focally positive. Immunohistochemical staining for the Ki-
67 labeling index (the percentage of positive cells stained with proliferation marker Ki-67 antibody) is 
40% (e). 
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